Cipla Ltd News

Cipla shares rise 3.5% after Q1; brokerages cautious, trim target

Cipla reported a 39.2 per cent fall in net profit for the first quarter to ₹789.05 crore on a year-on-year basis. Revenue for the quarter was up at ₹7,119.28 crore

Cipla's Q1 net falls 39% on US business; maintains FY27 margin guidance

The drugmaker attributed the decline to a high base in North America, retained its FY27 Ebitda margin guidance and expects new product launches to support growth

Cipla Q1 result: Net profit falls 39.2% to ₹789 cr; Dinesh Jain named CFO

Revenue from operations rose 2.3 per cent ‌to ₹7,119 crore, beating estimates of ₹7,073 crore

Cipla Q1 net profit falls 39% to ₹789 crore as expenses rise nearly 15%

Total expenses rose 14.7 per cent to ₹6,248.25 crore, outpacing reported revenue growth; Cipla also changed the presentation of promotional spending in its accounts

Q1 results: Infosys, Cipla, Indigo Airlines, IEX among 63 firms on July 23

Q1 results updates: Firms including Coromandel International, Mphasis, Chennai Petroleum Corporation, and Motilal Oswal Financial Services are also to release their April-June earnings today

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

F&O strategy: Analyst recommends Bull Spread on Cipla, United Spirits

Here's why Nandish Shah technical research analyst of HDFC Securities recommends a 'Bull Spread' strategy on Cipla and United Spirits derivatives for the July series.

Nifty Pharma extends rally, up 2%; Piramal Pharma, Laurus gain up to 10%

Analysts said that a combination of defensive buying, strong earnings visibility, export tailwinds, and sector rotation is driving the rally in pharma stocks.

Cipla appoints Shivam Puri as CEO of 'One India Business' from July 1

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Cipla expands respiratory, specialty manufacturing across India, China, US

Filed 10 applications with USFDA in FY26 to build a pipeline of differentiated products for regulated markets

Stocks to Watch today: Vedanta, Cipla, Dabur, Vi, Oil India, CDSL and more

Stocks to watch today: Vedanta, Cipla, Dabur, Vi, Oil India, CDSL, Ratnaveer Precision, NLC India, Sagility among others will in focus today.

Dividend stocks: RIL, Ashok Leyland, 13 others to remain in focus next week

Dividend stocks: Here is the complete list of stocks that will go ex-dividend next week

Pace of new product launches, filings key for Cipla's future growth

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

Cipla soars 8% despite disappointing Q4; what's driving pharma stock?

Going forward Cipla's management expects to pick up momentum in FY27 and aspires $1 billion revenue from the US itself.

Cipla Q4 profit plunges 55% to ₹554.6 cr amid US drag, higher R&D spend

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply

Cipla Q4 results: Net profit falls 54.6% to ₹555 crore, revenue drops 2.8%

Total revenue from operations fell 2.8 per cent to ₹6,541 crore, below the average expectations of ₹6,749 crore, hurt by a sales decline in its key North America market

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

Stocks to Watch today: Airtel, Tata Power, Cipla, RVNL, Dixon Tech and more

Stocks to watch today: Jewellery stocks, Tata Power, RVNL, Airtel, Cipla, Dixon Technologies, Dr Reddy's, Berger Paints are among others that will remain in focus today.